PT Kalbe Farma Tbk (KLBF) Q2 2026 earnings summary

Executive summary

• Net sales grew 14.1% year-over-year to IDR 19.5 trillion for 1H 2026, driven by volume growth across all segments.

• Net profit declined 2.8% year-over-year to IDR 1.92 trillion, impacted by higher COGS, operating expenses, and non-operating items.

• Total assets increased to IDR 33.1 trillion as of June 30, 2026.

• Gross profit margin decreased to 37.6% from 41.0% due to raw material costs and product mix.

• Strategic partnerships and investments advanced, including new ventures in biologics, radiopharmaceuticals, and international expansion.

Financial highlights

• Operating profit rose 1.3% year-over-year to IDR 2.48 trillion, with margin down to 12.7%.

• EBITDA margin at 14.4% for 1H 2026.

• Cash and cash equivalents increased 11.6% YTD to IDR 4.83 trillion.

• Total equity increased to IDR 25.76 trillion from IDR 24.73 trillion at year-end 2025.

• Gross profit rose to IDR 7.32 trillion from IDR 7.00 trillion year-over-year.

Outlook and guidance

• Focus on innovation, brand rejuvenation, and expanding preventive health categories.

• Continued investment in local manufacturing and digital distribution to support long-term growth.

• Ongoing mitigation of currency and raw material risks, with close monitoring of geopolitical and macroeconomic volatility.